Researchers managing multiple reconstituted vials need organized storage and clear labeling
Synthesized by Nikolaus Hansl in the 1970s, this synthetic compound (methyl 3-(2-(benzyl(methyl)amino)ethyl)benzoate hydrochloride) still stands as one of the most intriguing single-study cognitive enhancers ever documented
Notably, this GIP-related enhancement of energy expenditure is not dependent on classical adipose tissue browning, as we did not observe upregulation of browning/beiging signature genes ( Ucp1 , Prdm16 , Dio2 , Cidea ) in eWAT

GLP-1 receptor agonists Primary mechanism(s) of action Increase glucose-dependent insulin secretion, reduce post-prandial glucagon, and delay gastric emptying (resulting in reduced after meal glucose levels and increased satiety) Examples Exenatide (Byetta 10 mcg Pen, Byetta 5 mcg Pen, Bydureon BCise 2 mcg Pen) Dosage Immediate release (Byetta) Initial: 5 mcg subcutaneous injection twice daily a maximum of 60 minutes before morning and evening meals, or before the two main meals of the day Maximum: 10 mcg subcutaneous injection twice daily a maximum of 60 minutes before morning and evening meals, or before the two main meals of the day Extended release (Bydureon BCise) Initial: 2 mg subcutaneous injection once weekly Maximum: 2 mg subcutaneous injection weekly Lixisenatide (Adlyxin) Short-acting Dosage Initial: 10 mcg subcutaneous injection once daily, up to one hour before the first meal of the day, for 14 days